Jeanette Dupont Jensen
Overview
Explore the profile of Jeanette Dupont Jensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Langkjer S, Kenholm J, Jensen J, Wedervang K, Brixen A, Grunnet M, et al.
Future Oncol
. 2019 Jun;
15(22):2561-2569.
PMID: 31215242
Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC,...
12.
Falstie-Jensen A, Kjaersgaard A, Lorenzen E, Jensen J, Reinertsen K, Dekkers O, et al.
Breast Cancer Res
. 2019 Mar;
21(1):44.
PMID: 30902106
Background: Hypothyroidism may occur as a late effect of breast cancer-directed treatment, particularly after radiotherapy, but little is known whether hypothyroidism affects the prognosis after breast cancer. We investigated the...
13.
Zardavas D, Te Marvelde L, Milne R, Fumagalli D, Fountzilas G, Kotoula V, et al.
J Clin Oncol
. 2018 Feb;
36(10):981-990.
PMID: 29470143
Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient...
14.
Kroigard A, Larsen M, Laenkholm A, Knoop A, Jensen J, Bak M, et al.
PLoS One
. 2018 Jan;
13(1):e0189887.
PMID: 29293529
Cancer results from alterations at essential genomic sites and is characterized by uncontrolled cell proliferation, invasion and metastasis. Identification of driver genes of metastatic progression is essential, as metastases, not...
15.
Kroigard A, Larsen M, Brasch-Andersen C, Laenkholm A, Knoop A, Jensen J, et al.
Sci Rep
. 2017 Mar;
7:43813.
PMID: 28276460
A main controversy in cancer research is whether metastatic abilities are present in the most advanced clone of the primary tumor or result from independently acquired aberrations in early disseminated...
16.
Jensen J, Knoop A, Ewertz M, Laenkholm A
Breast Cancer Res Treat
. 2011 Jun;
132(2):511-21.
PMID: 21667123
At recurrence of breast cancer, the therapeutic target is the metastases. However, it is current practice to base the choice of systemic treatment on the biomarker profile of the primary...
17.
Jensen J, Laenkholm A, Knoop A, Ewertz M, Bandaru R, Liu W, et al.
Clin Cancer Res
. 2010 Oct;
17(4):667-77.
PMID: 20940279
Purpose: PIK3CA mutations are frequent in breast cancer and activate the PI3K/Akt pathway. Unexpectedly, PIK3CA mutation appears in general to be associated with better outcome. In a cohort of patients...
18.
Jensen H, Nielsen H, Jensen J, Fristrup C, Nielsen M, Pfeiffer P
Ugeskr Laeger
. 2008 Mar;
170(8):639-41.
PMID: 18364156
Introduction: Only 10-20% of patients with pancreatic cancer are offered operation with curative intent. If this is not possible, treatment with pre-operative radiotherapy in combination with chemotherapy offers the opportunity...